CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.

被引：0
|
作者：
Gerhart, J. [1 ]
Edginton, A. [2 ]
Watt, K. [3 ]
Cohen-Wolkowiez, M. [3 ]
Harper, B. [3 ]
Muller, W. [4 ]
Delmore, P. [5 ]
Atz, A. [6 ]
Payne, E. [7 ]
Erinjeri, J. [7 ]
Lin, S. [7 ]
Gonzalez, D. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ Waterloo, Kitchener, ON, Canada
[3] Duke Clin Res Inst, Durham, NC USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA
[5] Wesley Med Ctr, Wichita, KS USA
[6] Med Univ South Carolina, Charleston, SC 29425 USA
[7] Emmes, Rockville, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-106
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [1] CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
    Gerhart, J.
    Edginton, A.
    Watt, K.
    Cohen-Wolkowiez, M.
    Harper, B.
    Muller, W.
    Delmore, P.
    Atz, A.
    Payne, E.
    Erinjeri, J.
    Lin, S.
    Gonzalez, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S15 - S15
  • [2] Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants
    Pan, Xian
    Yeo, Karen Rowland
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (01) : 182 - 191
  • [3] EVALUATION OF CYP2B6 INDUCTION AND PREDICTION OF CLINICAL DDI USING PBPK MODELING.
    Ke, A.
    Barter, Z.
    Yeo, K. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S69 - S69
  • [4] Physiologically Based Pharmacokinetic (PBPK) Modeling in Children
    Barrett, J. S.
    Alberighi, O. Della Casa
    Laeer, S.
    Meibohm, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (01) : 40 - 49
  • [5] Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans
    Luttringer, O
    Theil, FP
    Poulin, P
    Schmitt-Hoffmann, AH
    Guentert, TW
    Lavé, T
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (10) : 1990 - 2007
  • [6] CYP2B6 Pharmacogenetics-Based In Vitro-In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling
    Xu, Cong
    Quinney, Sara K.
    Guo, Yingying
    Hall, Stephen D.
    Li, Lang
    Desta, Zeruesenay
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (12) : 2004 - 2011
  • [7] ENTRECTINIB DOSING STRATEGIES WITH CYP3A4 PERPETRATORS USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING.
    Djebli, N.
    Buchheit, V.
    Cleary, Y.
    Parrott, N.
    Frey, N.
    Mercier, F.
    Phipps, A.
    Meneses-Lorente, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S50 - S50
  • [8] METHADONE ENANTIOMERS METABOLISM AND CLEARANCE ARE IMPAIRED IN INDIVIDUALS WITH CYP2B6*6 GENOTYPE
    Kharasch, E. D.
    Parchomski, J.
    Regina, K.
    Blood, J.
    Yang, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S53 - S54
  • [9] Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
    Marok, Fatima Zahra
    Fuhr, Laura Maria
    Hanke, Nina
    Selzer, Dominik
    Lehr, Thorsten
    PHARMACEUTICS, 2021, 13 (03) : 1 - 23
  • [10] Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
    Grzegorzewski, Jan
    Brandhorst, Janosch
    Koenig, Matthias
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345